Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Nephrology

The Long View: Monitoring, Surveillance, and Family Screening

At a Glance

Primary hyperoxaluria requires personalized, ongoing monitoring of kidney function, urine and blood oxalate, and kidney imaging. People with advanced disease may need eye, heart, or bone screening, and asymptomatic relatives should receive targeted genetic testing.

Managing Primary Hyperoxaluria (PH) is a marathon, not a sprint. Because the disease can be unpredictable, a consistent schedule of “surveillance”—the medical term for regular monitoring—is your best defense against unexpected kidney damage or systemic complications [1][2].

Your Routine Surveillance Schedule

The frequency of your tests depends on your subtype and how well your kidneys are functioning. While your medical team will create a personalized plan, standard monitoring typically includes:

  • Kidney Function (eGFR): This blood test measures how well your kidneys are filtering waste. In PH, function can remain stable for years and then change suddenly, so regular checks are essential [2].
  • Urinary Oxalate (24-Hour): This remains an important tool for tracking how much oxalate your kidneys are clearing and how well your current treatments (like hydration or RNAi) are working [3]. Because oxalate levels can swing by more than 30% day-to-day, a single “spot” test is often not enough; a full 24-hour collection is much more accurate [3].
  • Plasma Oxalate: As kidney function declines (especially into advanced CKD), blood levels become more important than urine levels for assessing systemic risk [2][4]. To get an accurate trend, it is vital to use the same laboratory and testing method every time, as results can vary significantly between different labs [5].
  • Kidney Imaging: Regular ultrasounds are used to monitor nephrocalcinosis (calcium deposits in the kidney tissue) and new stone formation [6]. Ultrasound is generally preferred, especially for children, to limit radiation exposure; CT scans are reserved for specific clinical questions.

Screening for Systemic Oxalosis

When oxalate levels in the blood rise significantly, crystals can begin to deposit in other organs. Specialist-directed screening is typically triggered for patients with advanced kidney disease or very high plasma oxalate [7][8]. These are not universal routine tests for early, asymptomatic patients.

  1. The Eyes (Retina): Oxalate can scar the back of the eye. A specialist may perform a retinal exam (often including photography or OCT scans) to look for crystals [9]. Because this damage is often permanent once it starts, early detection in advanced disease is key [9].
  2. The Heart: An echocardiogram (heart ultrasound) checks for heart stiffness caused by oxalate [10]. Modern “strain imaging” may be requested by your metabolic team if risk is high [10].
  3. The Bones: If you experience new bone pain or fractures, specialized imaging like an MRI or CT can check for oxalate osteopathy (deposits in the bone marrow) [11][12].

Managing “Scan Anxiety”

It is completely normal to feel a wave of “scan anxiety”—the dread or stress that builds up before a scheduled test or while waiting for results. For many PH families, every blood draw or ultrasound feels like a high-stakes “pass/fail” exam for their health. Remember that these tests are tools, not judgments; they provide the data your care team needs to adjust your treatment and keep you safe.

The Absolute Necessity of Family Screening

PH is an autosomal recessive condition, meaning parents are usually healthy “carriers.” If both parents carry the relevant pathogenic variant, there is a 25% chance in each pregnancy of the child inheriting the disease [13][14].

  • Asymptomatic Siblings: This is the most critical group to test. In some families, one child may have severe symptoms while their sibling has “silent” disease with no stones at all—yet that sibling may still be at risk for kidney damage [15][16]. At-risk relatives should be offered targeted testing, regardless of whether they “feel fine” [15].
  • Genetic Counseling: If you are planning a family, genetic counselors can help you understand the risks and discuss options like prenatal diagnosis or preimplantation genetic testing (testing embryos before pregnancy) [17][18].
  • Newborns: If a family history of PH1 is known, a newborn should receive prompt specialist and genetic evaluation to confirm their subtype and biochemical status. This allows doctors to determine if early treatments are appropriate [19][20].

Common questions in this guide

How often should people with primary hyperoxaluria be monitored?
There is no single schedule for everyone because monitoring depends on the PH subtype and kidney function. Common monitoring includes eGFR, 24-hour urine oxalate, plasma oxalate, and kidney ultrasound, with the care team determining how often each test is needed.
Why is a 24-hour urine test used instead of a spot urine test for PH?
Urinary oxalate can vary substantially from day to day, so one spot sample may not reflect usual oxalate excretion. A complete 24-hour collection generally gives a more reliable measure for tracking the condition and response to treatment.
When would I need eye, heart, or bone screening for primary hyperoxaluria?
These tests are usually considered when kidney disease is advanced or plasma oxalate is very high, rather than as routine tests for every person early in the condition. New vision changes, bone pain, or fractures should be reported because they may prompt additional evaluation.
Why should plasma oxalate be measured at the same laboratory?
Different laboratories and testing methods can produce meaningfully different plasma oxalate results. Using the same laboratory and method makes it easier for the care team to identify a true trend over time.
Should siblings be tested for primary hyperoxaluria if they feel well?
Yes, at-risk siblings and other relatives may have silent disease without kidney stones or noticeable symptoms. If the family variant is known, targeted genetic testing can identify relatives who need specialist evaluation and monitoring.
What is the chance of passing primary hyperoxaluria to a child if both parents are carriers?
When both parents carry the relevant pathogenic variant, each pregnancy has a 25% chance of producing a child with primary hyperoxaluria. A genetic counselor can explain prenatal diagnosis, preimplantation genetic testing, and testing options for relatives.
What should happen if a newborn has a family history of PH1?
The newborn should receive prompt specialist and genetic evaluation to confirm the subtype and check biochemical status. Early evaluation helps the medical team decide whether monitoring or treatment is needed.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Primary hyperoxaluria.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my current CKD stage and plasma oxalate levels, what is the specific surveillance schedule we should follow for blood and urine tests?
  2. 2.At what point in my kidney function decline would we trigger specialized tests like retinal exams or strain echocardiography?
  3. 3.Which laboratory are we using for plasma oxalate, and can we ensure we use the same one every time to keep our results consistent?
  4. 4.Can you provide a referral to a genetic counselor to discuss targeted testing for my siblings?
  5. 5.If we are planning a future pregnancy, what are the specific steps for prenatal or preimplantation genetic testing for PH?

References

References (20)
  1. 1

    Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope.

    Groothoff JW, Metry E, Deesker L, et al.

    Nature reviews. Nephrology 2023; (19(3)):194-211 doi:10.1038/s41581-022-00661-1.

    PMID: 36604599
  2. 2

    End Points for Clinical Trials in Primary Hyperoxaluria.

    Milliner DS, McGregor TL, Thompson A, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2020; (15(7)):1056-1065 doi:10.2215/CJN.13821119.

    PMID: 32165440
  3. 3

    Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up.

    Garrelfs SF, Rumsby G, Peters-Sengers H, et al.

    Kidney international 2019; (96(6)):1389-1399 doi:10.1016/j.kint.2019.08.018.

    PMID: 31685312
  4. 4

    Primary and secondary hyperoxaluria: Understanding the enigma.

    Bhasin B, Ürekli HM, Atta MG

    World journal of nephrology 2015; (4(2)):235-44 doi:10.5527/wjn.v4.i2.235.

    PMID: 25949937
  5. 5

    Plasma oxalate: comparison of methodologies.

    Stokes F, Acquaviva-Bourdain C, Hoppe B, et al.

    Urolithiasis 2020; (48(6)):473-480 doi:10.1007/s00240-020-01197-4.

    PMID: 32472220
  6. 6

    Determinants of Kidney Failure in Primary Hyperoxaluria Type 1: Findings of the European Hyperoxaluria Consortium.

    Metry EL, Garrelfs SF, Deesker LJ, et al.

    Kidney international reports 2023; (8(10)):2029-2042 doi:10.1016/j.ekir.2023.07.025.

    PMID: 37849991
  7. 7

    Treatment of primary hyperoxaluria type 1.

    Gupta A, Somers MJG, Baum MA

    Clinical kidney journal 2022; (15(Suppl 1)):i9-i13 doi:10.1093/ckj/sfab232.

    PMID: 35592620
  8. 8

    Natural History of Clinical, Laboratory, and Echocardiographic Parameters of a Primary Hyperoxaluria Cohort on Long Term Hemodialysis.

    Sas DJ, Enders FT, Gunderson TM, et al.

    Frontiers in medicine 2021; (8()):592357 doi:10.3389/fmed.2021.592357.

    PMID: 33898474
  9. 9

    Oxalate retinopathy is irreversible despite early combined liver-kidney transplantation in primary hyperoxaluria type 1.

    Atiskova Y, Dulz S, Schmäschke K, et al.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2019; (19(12)):3328-3334 doi:10.1111/ajt.15484.

    PMID: 31152479
  10. 10

    Subclinical myocardial disease in patients with primary hyperoxaluria and preserved left ventricular ejection fraction: a two-dimensional speckle-tracking imaging study.

    Lagies R, Udink Ten Cate FEA, Feldkötter M, et al.

    Pediatric nephrology (Berlin, Germany) 2019; (34(12)):2591-2600 doi:10.1007/s00467-019-04330-7.

    PMID: 31440827
  11. 11

    Three Tesla magnetic resonance imaging detects oxalate osteopathy in patients with primary hyperoxaluria type I.

    Merz LM, Born M, Kukuk G, et al.

    Pediatric nephrology (Berlin, Germany) 2023; (38(7)):2083-2092 doi:10.1007/s00467-022-05836-3.

    PMID: 36472654
  12. 12

    Long-term complications of systemic oxalosis in children-a retrospective single-center cohort study.

    Ben-Shalom E, Cytter-Kuint R, Rinat C, et al.

    Pediatric nephrology (Berlin, Germany) 2021; (36(10)):3123-3132 doi:10.1007/s00467-021-05002-1.

    PMID: 33651179
  13. 13

    Global genetic prevalence estimates of primary hyperoxaluria are greater than previously reported.

    Mandrile G, Rumsby G, Sciannameo V, et al.

    Clinical kidney journal 2025; (18(7)):sfaf194 doi:10.1093/ckj/sfaf194.

    PMID: 40873808
  14. 14

    Next-generation sequencing in identification of pathogenic variants in primary hyperoxaluria among 21 Egyptian families: Identification of two novel AGXT gene mutations.

    Ahmed HA, Fadel FI, Abdel Mawla MA, et al.

    Molecular genetics & genomic medicine 2022; (10(8)):e1992 doi:10.1002/mgg3.1992.

    PMID: 35661454
  15. 15

    Clinical features of genetically confirmed patients with primary hyperoxaluria identified by clinical indication versus familial screening.

    Sas DJ, Enders FT, Mehta RA, et al.

    Kidney international 2020; (97(4)):786-792 doi:10.1016/j.kint.2019.11.023.

    PMID: 32093915
  16. 16

    Genetic assessment in primary hyperoxaluria: why it matters.

    Mandrile G, Beck B, Acquaviva C, et al.

    Pediatric nephrology (Berlin, Germany) 2023; (38(3)):625-634 doi:10.1007/s00467-022-05613-2.

    PMID: 35695965
  17. 17

    [OXALATE STONES ARE PREVALENT AMONG DRUZE AND MUSLIM ARABS IN THE GALILEE].

    Kalfon L, Weissman I, Hershkovits M, et al.

    Harefuah 2017; (156(3)):156-162.

    PMID: 28551940
  18. 18

    Clinical and molecular characterization of primary hyperoxaluria in Egypt.

    Soliman NA, Elmonem MA, Abdelrahman SM, et al.

    Scientific reports 2022; (12(1)):15886 doi:10.1038/s41598-022-17980-9.

    PMID: 36151119
  19. 19

    Lumasiran at birth changes the trajectory of primary hyperoxaluria type 1: same disease, different outcomes in two affected siblings.

    Peruzzi L, Leporati M,

    Journal of nephrology 2025; (38(8)):2417-2422 doi:10.1007/s40620-025-02325-2.

    PMID: 40632478
  20. 20

    Primary Hyperoxaluria Type 1: A Cause for Infantile Renal Failure and Massive Nephrocalcinosis.

    Kurt-Sukur ED, Özçakar ZB, Fitöz S, et al.

    Klinische Padiatrie 2015; (227(5)):293-5 doi:10.1055/s-0035-1554638.

    PMID: 26090995

This page explains monitoring and family screening for primary hyperoxaluria for educational purposes only and does not replace medical advice. Your nephrology, metabolic, and genetics teams should set your testing schedule and interpret results for your family.